New studies on retatrutides, a dual stimulant for incretin hormone and gastric inhibitory polypeptide, suggest significant findings in managing obesity and type 2 diabetes. Preliminary information from clinical trials point to notable reductions in body bulk and enhanced glucose control. Additional examination is focused on long-term harmlessnes… Read More